Diploma (LON:DPLM - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at Berenberg Bank in a report released on Tuesday, MarketBeat reports. They presently have a GBX 5,750 price objective on the stock. Berenberg Bank's target price points to a potential upside of 6.38% from the stock's previous close.
DPLM has been the topic of a number of other reports. JPMorgan Chase & Co. restated a "neutral" rating and set a GBX 4,440 price target on shares of Diploma in a research note on Wednesday, August 6th. Shore Capital restated a "hold" rating and set a GBX 5,100 price target on shares of Diploma in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of GBX 5,097.50.
Read Our Latest Stock Analysis on DPLM
Diploma Trading Up 1.4%
DPLM traded up GBX 75 during trading hours on Tuesday, reaching GBX 5,405. The company's stock had a trading volume of 18,554,396 shares, compared to its average volume of 477,312. Diploma has a fifty-two week low of GBX 3,532 and a fifty-two week high of GBX 5,625. The stock has a market cap of £7.24 billion, a PE ratio of 4,348.35, a P/E/G ratio of 2.82 and a beta of 0.75. The business's 50-day moving average is GBX 5,224.41 and its 200-day moving average is GBX 4,592.24. The company has a debt-to-equity ratio of 62.17, a current ratio of 2.17 and a quick ratio of 0.80.
Diploma Company Profile
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.